Program
treprostinil
Also written as “Inhaled Treprostinil”, “treprostinil diethanolamine” and “Oral Treprostinil”.
Its studies are mostly in Pulmonary Arterial Hypertension · Hypertension, Pulmonary · Scleroderma, Systemic · Idiopathic Pulmonary Fibrosis · Chronic Limb-Threatening Ischemia, led by 5 companies.
Drug pageTreprostinil: every studyMany companies study it; this page follows only the 71 they lead. All 99 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| United Therapeuticsits history only | 625 open or running | phase 4since Apr 14, 2003 | Oct 18, 1999 | Nov 2027phase 3 · NCT05943535 |
| Liquidia Technologies | 64 open or running | phase 4since Aug 7, 2026 | Jan 3, 2018 | Feb 2027phase 2 · NCT07748000 |
| Mannkindits history only | 10 open or running | phase 1since Mar 1, 2018 | Mar 1, 2018 | none ahead |
| Pharmosa Biopharmits history only | 10 open or running | phase 1since Jul 23, 2019 | Jul 23, 2019 | none ahead |
| SciPharm SàRLits history only | 10 open or running | phase 3since Aug 12, 2011 | Aug 12, 2011 | none ahead |
Also a collaborator on its studies: PPD Development, LP, Nuventra, FGK Clinical Research and CVie Therapeutics.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Liquidia Technologies only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jan 3, 2018First study: phase 3 study in Familial Primary Pulmonary HypertensionFirst studyNCT03399604 · 121 enrolled · United States
- Mar 4, 2019Phase 2 study in Pulmonary Arterial HypertensionNCT03884465 · 15 enrolled · France, Germany
- Jun 5, 2019Phase 3 study in Familial Primary Pulmonary HypertensionNCT03992755 · 92 enrolled · United States
- Jun 9, 2019Named treprostinilINNProposed as its International Nonproprietary Name in WHO's List 121
- Dec 11, 2025Phase 3 study in Hypertension, PulmonaryNCT07285655 · 344 planned · United States, Australia, Austria and more
- Jul 31, 2026Phase 2 study in Scleroderma, SystemicNCT07748000 · 75 planned
- Aug 7, 2026Phase 4 study in Pulmonary Arterial HypertensionNCT07759804 · 20 planned · United States
Ahead
- Feb 2027Primary completion: phase 2 study in Scleroderma, SystemicNCT07748000
- May 2027Primary completion: phase 4 study in Pulmonary Arterial HypertensionNCT07759804
- Jul 2029Primary completion: phase 3 study in Hypertension, PulmonaryNCT07285655
TargetBeta
“Prostanoid IP receptor agonist; Prostanoid IP receptor agonist; Prostanoid IP receptor agonist”ChEMBL 37, by rule
Other programs on PTGIR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| selexipagrule | Johnson & Johnson | phase 4 | 23 |
Studies
All 6 Liquidia Technologies leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07759804Pulmonary Arterial Hypertension · United States | 4 | Recruiting | May 2027 | 20 |
| NCT07748000Scleroderma, Systemic | 2 | Not yet recruiting | Feb 2027 | 75 |
| NCT07285655Hypertension, Pulmonary · United States, Australia, Austria and more | 3 | Recruiting | Jul 2029 | 344 |
| NCT03992755Familial Primary Pulmonary Hypertension · United States | 3 | Active, not recruiting | May 31, 2025 | 92 |
| NCT03884465Pulmonary Arterial Hypertension · France, Germany | 2 | Terminated | Dec 23, 2020 | 15 |
| NCT03399604Familial Primary Pulmonary Hypertension · United States | 3 | Completed | May 6, 2019 | 121 |
How it is read
Names in the registry
- “Inhaled Treprostinil”, 7 entries
- “treprostinil diethanolamine”, 6 entries
- “Oral Treprostinil”, 5 entries
- “treprostinil sodium”, 5 entries
- “UT-15C SR”, 4 entries
Conditions, from the studies’ own filings
- Pulmonary Arterial Hypertension, 38 studies
- Hypertension, Pulmonary, 17 studies
- Scleroderma, Systemic, 4 studies
- Idiopathic Pulmonary Fibrosis, 3 studies
- Chronic Limb-Threatening Ischemia, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.